The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Acrivon Therapeutics Inc shares valued at $17,218 were purchased by Devroe Eric on Jan 13 ’26. At $1.72 per share, Devroe Eric acquired 10,000 shares. The insider’s holdings grew to 75,308 shares worth approximately $0.14 million following the completion of this transaction.
Also, PERCEPTIVE ADVISORS LLC sold 437,881 shares, netting a total of over 617,412 in proceeds. Following the sale of shares at $1.41 each, the insider now holds 3,403,025 shares.
Before that, PERCEPTIVE ADVISORS LLC had sold 298,886 shares from its account. In a trade valued at $400,507, the 10% Owner traded Acrivon Therapeutics Inc shares for $1.34 each. Upon closing the transaction, the insider’s holdings decreased to 298,886 shares, worth approximately $5.8 million.
Analysts at KeyBanc Capital Markets started covering the stock with ‘”an Overweight”‘ outlook in a report released in late January. As of September 16, 2024, Ladenburg Thalmann has increased its “Neutral” rating to a “Buy” for ACRV. Earlier on April 29, 2024, Ladenburg Thalmann downgraded its rating. Their new recommendation was “a Neutral” for ACRV stock which previously was a “a Buy”.
Analyzing ACRV Stock Performance
On last trading session, Acrivon Therapeutics Inc [NASDAQ: ACRV] rose 2.19% to $1.87. The stock’s lowest price that day was $1.79, but it reached a high of $1.925 in the same session. During the last five days, there has been a drop of approximately -3.11%. Over the course of the year, Acrivon Therapeutics Inc shares have dropped approximately -66.37%.
Support And Resistance Levels for Acrivon Therapeutics Inc (ACRV)
RSI (Relative Strength Index) is 42.03 on the 14-day chart, showing neutral technical sentiment.
Is Acrivon Therapeutics Inc subject to short interest?
Stocks of Acrivon Therapeutics Inc saw a sharp rise in short interest on 2025-12-31 jumping by 0.97 million shares to 5.33 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 4.36 million shares. A jump of 18.2% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 11.85 of the overall float, the days-to-cover ratio (short ratio) jumped to 11.85.
Which companies own the most shares of Acrivon Therapeutics Inc (ACRV)?
In terms of Acrivon Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 20 in the next 12 months, up nearly 992.9% from the previous closing price of $1.83. Analysts anticipate Acrivon Therapeutics Inc stock to reach 30 by 2026, with the lowest price target being 17. In spite of this, 7 analysts ranked Acrivon Therapeutics Inc stock as Buy at the end of 2026. On March 01, 2024, JMP Securities assigned a price target of “a Mkt outperform” to the stock and initiated coverage with a $14.
